Traumatic brain injury (TBI) is a major health concern and leading cause of death and disability in young adults in the United Kingdom and worldwide; however, there is a paucity of disease modifying therapies for the treatment of TBI. This review investigates the potential of the renin-angiotensin system (RAS) as a treatment pathway for TBI in adults. Relevant electronic databases were searched on December 18, 2019, and updated May 16, 2021. All English language articles with adult human or animal populations investigating RAS drugs as an intervention for TBI or reporting genetic evidence relevant to the RAS and TBI were screened. Eighteen pre-clinical randomized controlled trials (RCTs) (n = 2269) and two clinical cohort studies (n = 771) were included. Meta-analyses of six pre-clinical RCTs (n = 99) indicated that candesartan improved neurological function over the short term (< 7 days: standardized mean difference [SMD] 0.61, 95% confidence interval [CI] 0.19–1.03, I2 = 0%) and over the long term (≥ 7 days: SMD 1.06, 95% CI 0.38; 1.73, I2 = 0%) post-TBI. Findings were similar for most secondary outcomes. There was a suggestion of benefit from other RAS-targeting drugs, although evidence was limited because there were few small studies. There was insufficient evidence to enable strong assessment of these drugs on mortality post-TBI. We conclude that angiotensin-receptor blockers, especially candesartan, show positive outcomes post-TBI in pre-clinical studies with moderate quality of evidence (Grading of Recommendations Assessment, Development and Evaluation [GRADE]). More research into the effect of regulatory-RAS targeting drugs is needed. Clinical trials of candesartan following TBI are recommended, because there is strong and consistent evidence of neuroprotection shown by these pre-clinical studies.
Get full access to this article
View all access options for this article.
References
1.
ParsonageM. (2016). Traumatic Brain Injury and Offending: An Economic Analysis. London: Barrow Cadbury Trust Centre for Mental Health.
2.
GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 56–87.
NordstromA., and NordstromP. (2018). Traumatic brain injury and the risk of dementia diagnosis: a nationwide cohort study. PLoS Med. 15, e1002496.
5.
GrahamN.S., and SharpD.J. (2019). Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. J. Neurol. Neurosurg. Psychiatry, 90, 1221–1233.
6.
MalecJ.F., BrownA.W., LeibsonC.L., FlaadaJ.T., MandrekarJ.N., DiehlN.N., and PerkinsP.K. (2007). The mayo classification system for traumatic brain injury severity. J. Neurotrauma, 24, 1417–1424.
7.
NgS.Y., and LeeA.Y.W. (2019). Traumatic brain injuries: pathophysiology and potential therapeutic targets. Front. Cell. Neurosci. 13, 528.
8.
KaurP., and SharmaS. (2018). Recent advances in pathophysiology of traumatic brain injury. Curr. Neuropharmacol. 16, 1224–1238.
9.
Rodriguez-GrandeB., IchkovaA., LemarchantS., and BadautJ. (2017). Early to long-term alterations of CNS barriers after traumatic brain injury: considerations for drug development. AAPS J, 19, 1615–1625.
10.
ShlosbergD., BeniflaM., KauferD., and FriedmanA. (2010). Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 6, 393–403.
11.
CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators (2021). Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial. Eur. J. Trauma Emerg. Surg. 47, 261–268.
12.
MacdonaldP.S. (2015). Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. Clin. Ther. 37, 2199–2205.
13.
SolomonS.D., ZileM., PieskeB., VoorsA., ShahA., Kraigher-KrainerE., ShiV., BransfordT., TakeuchiM., GongJ., LefkowitzM., PackerM., and McMurrayJ.J. (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 380, 1387–1395.
14.
AlvesJ.L., RatoJ. and SilvaV. (2019). Why does brain trauma research fail?. World Neurosurg. 130, 115–121.
15.
CoxC.S.Jr., JuranekJ., and BediS. (2019). Clinical trials in traumatic brain injury: cellular therapy and outcome measures. Transfusion, 59, 858–868.
16.
SteinD. (2017). Why did the phase III clinical trials for progesterone in TBI fail?. an analysis of three potentially critical factors. New Ther. TBI. 3–18.
17.
SteinD.G. (2015). Embracing failure: what the Phase III progesterone studies can teach about TBI clinical trials. Brain Inj. 29, 1259–1272.
18.
SolimanN., RiceA.S.C., and VollertJ. (2020). A practical guide to preclinical systematic review and meta-analysis. Pain, 161, 1949–1954.
19.
WrightJ.W., and HardingJ.W. (2011). Brain renin-angiotensin—a new look at an old system. Prog. Neurobiol. 95, 49–67.
20.
Labandeira-GarciaJ.L., Rodriguez-PerezA.I., Garrido-GilP., Rodriguez-PallaresJ., LanciegoJ.L., and GuerraM.J. (2017). Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front. Aging Neurosci. 9, 129.
21.
SuQ., HuoC.J., LiH.B., LiuK.L., LiX., YangQ., SongX.A., ChenW.S., CuiW., ZhuG.Q., ShiX.L., LiuJ.J., and KangY.M. (2017). Renin-angiotensin system acting on reactive oxygen species in paraventricular nucleus induces sympathetic activation via AT1R/PKCgamma/Rac1 pathway in salt-induced hypertension. Sci. Rep. 7, 43107.
22.
GarridoA.M., and GriendlingK.K. (2009). NADPH oxidases and angiotensin II receptor signaling. Mol. Cell Endocrinol. 302, 148–158.
23.
JanatpourZ.C., and SymesA.J. (2020). The extended renin-angiotensin system: a promising target for traumatic brain injury therapeutics. Neural Regen. Res. 15, 1025–1026.
24.
DusingR. (2016). Mega clinical trials which have shaped the RAS intervention clinical practice. Ther. Adv. Cardiovasc. Dis. 10, 133–150.
25.
WrightJ.W. and HardingJ.W. (2019). Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer's disease. J. Alzheimers Dis. 67, 469–480.
26.
AshbyE.L., and KehoeP.G. (2013). Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin. Investig. Drugs, 22, 1229–1242.
27.
Abdel-FattahM.M., MessihaB.A.S., and MansourA.M. (2018). Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats. Naunyn Schmiedebergs Arch. Pharmacol. 391, 1003–1020.
28.
WangJ., HoL., ChenL., ZhaoZ., ZhaoW., QianX., HumalaN., SerorI., BartholomewS., RosendorffC., and PasinettiG.M. (2007). Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393–3402.
29.
DanielyanL., KleinR., HansonL.R., BuadzeM., SchwabM., GleiterC.H., and FreyW.H. (2010). Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 13, 195–201.
30.
SaavedraJ.M. (2012). Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. (Lond) 123, 567–590.
31.
SaavedraJ.M. (2017). Beneficial effects of Angiotensin II receptor blockers in brain disorders. Pharmacol. Res. 125, 91–103.
32.
DingH., LiaoL., ZhengX., WangQ., LiuZ., XuG., LiX., and LiuL. (2021). beta-Blockers for traumatic brain injury: A systematic review and meta-analysis. J. Trauma Acute Care Surg. 90, 1077–1085.
33.
Florez-PerdomoW.A., Laiseca TorresE.F., SerratoS.A., JanjuaT., JoaquimA.F., and Moscote-SalazarL.R. (2021). A systematic review and meta-analysis on effect of beta-blockers in severe traumatic brain injury. Neurol. Res. 43, 609–615.
JacksonS.J., AndrewsN., BallD., BellantuonoI., GrayJ., HachoumiL., HolmesA., LatchamJ., PetrieA., PotterP., RiceA., RitchieA., StewartM., StrepkaC., YeomanM., and ChapmanK. (2017). Does age matter?. The impact of rodent age on study outcomes. Lab. Anim. 51, 160–169.
36.
The EndNote Team (2013). EndNote, X9, 64 bit. Philadelphia, PA: Clarivate.
BramlettH.M., and DietrichW.D. (2015). Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J. Neurotrauma, 32, 1834–1848.
46.
Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration, 2020.
47.
WilsonM.W.L.D.B. (2001). Practical Meta-Analysis. Thousand Oaks, CA: SAGA.
48.
HigginsJ.P.T., ChandlerJ., CumpstonM., LiT., PageM.J., and WelchV.A. (2021). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 Cochrane Database of Systematic Reviews.
49.
CumpstonM., LiT., PageM.J., ChandlerJ., WelchV.A., HigginsJ.P., and ThomasJ. (2019). Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev. 10, ED000142.
50.
Abdul-MuneerP.M., BhowmickS., and BriskiN. (2018). Angiotensin II causes neuronal damage in stretch-injured neurons: protective effects of losartan, an angiotensin T1 receptor blocker. Mol. Neurobiol. 55, 5901–5912.
51.
ArizaM., MatarinM.D., JunqueC., MataroM., ClementeI., MoralP., Antonia PocaM., GarnachoA., and SahuquilloJ. (2006). Influence of Angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 18, 39–44.
52.
AttilioP.J., SnapperD.M., RusnakM., IsaacA., SoltisA.R., WilkersonM.D., DalgardC.L., and SymesA.J. (2021). Transcriptomic analysis of mouse brain after traumatic brain injury reveals that the angiotensin receptor blocker candesartan acts through novel pathways. Front. Neurosci. 15, 636259.
53.
BooneD.R., WeiszH.A., WilleyH.E., TorresK.E.O., FaldutoM.T., SinhaM., SprattH., BoldingI.J., JohnsonK.M., ParsleyM.A., DeWittD.S., ProughD.S., and HellmichH.L. (2019). Traumatic brain injury induces long-lasting changes in immune and regenerative signaling. PLoS One, 14, e0214741.
54.
CatapanoJ.S., ChapmanA.J., DullM., AbbatematteoJ.M., HornerL.P., GodzikJ., BrigemanS., MorganC.D., WhitingA.C., LuM., ZabramskiJ.M., and FraserD.R. (2019). Association of angiotensin-converting enzyme inhibitors with increased mortality among patients with isolated severe traumatic brain injury. Neurocrit. Care, 31, 507–513.
55.
HajmohammadiM., KhaksariM., SoltaniZ., ShahrokhiN., NajafipourH., and AbbasiR. (2019). The effect of candesartan alone and its combination with estrogen on post-traumatic brain injury outcomes in female rats. Front. Neurosci. 13, 1043.
56.
Harford-WrightE., ThorntonE., and VinkR. (2010). Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci. Lett. 481, 26–29.
57.
JanatpourZ.C., KorotcovA., BosomtwiA., DardzinskiB.J., and SymesA.J. (2019). Subcutaneous administration of angiotensin-(1-7) improves recovery after traumatic brain injury in mice. J. Neurotrauma, 36, 3115–3131.
58.
KhaksariM., RajizadehM.A., BejeshkM.A., SoltaniZ., MotamediS., MoramdiF., IslamiM., ShafaS., and KhosraviS. (2018). Does inhibition of angiotensin function cause neuroprotection in diffuse traumatic brain injury?. Iran J. Basic Med. Sci. 21, 615–620.
59.
KimJ., KimN., JohnsonM., and YenariM. (2016). Angiotensin receptor type 1 deficiency attenuates brain damage and improves outcome after experimental traumatic brain injury. Stroke 47, ATP445.
60.
LippoldtA., BunnemannB., UekiA., RosenL., CintraA., HasselrotU., MetzgerR., HilgenfeldtU., BrosnihanB., GantenD., et al. (1994). On the plasticity of the cerebellar renin-angiotensin system: localization of components and effects of mechanical perturbation. Brain Res. 668, 144–159.
61.
SabelB.A., KardonG.B., and SteinD.G. (1983). Behavioral effects of intracerebral injections of renin and captopril in intact and brain-damaged rats. Brain Res. Bull. 11, 637–642.
62.
Timaru-KastR., GotthardtP., LuhC., HuangC., HummelR., SchaferM.K.E., and ThalS.C. (2019). Angiotensin II receptor 1 blockage limits brain damage and improves functional outcome after brain injury in aged animals despite age-dependent reduction in AT1 expression. Front. Aging Neurosci. 11, 63.
63.
Timaru-KastR., WyschkonS., LuhC., SchaibleE.V., LehmannF., MerkP., WernerC., EngelhardK., and ThalS.C. (2012). Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit. Care Med. 40, 935–944.
64.
UmschweifG., Liraz-ZaltsmanS., ShabashovD., AlexandrovichA., TrembovlerV., HorowitzM., and ShohamiE. (2014). Angiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury. Neurotherapeutics, 11, 665–678.
65.
UmschweifG., ShabashovD., AlexandrovichA.G., TrembovlerV., HorowitzM., and ShohamiE. (2014). Neuroprotection after traumatic brain injury in heat-acclimated mice involves induced neurogenesis and activation of angiotensin receptor type 2 signaling. J. Cereb. Blood Flow Metab. 34, 1381–1390.
66.
VillapolS., BalarezoM.G., AfframK., SaavedraJ.M., and SymesA.J. (2015). Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain, 138, 3299–3315.
67.
VillapolS., YaszemskiA.K., LoganT.T., Sanchez-LemusE., SaavedraJ.M., and SymesA.J. (2012). Candesartan, an angiotensin II AT(1)-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology, 37, 2817–2829.
68.
WeiX., HuC.C., ZhangY.L., YaoS.L., and MaoW.K. (2016). Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury. J. Huazhong Univ. Sci. Technolog. Med. Sci. 36, 576–583.
69.
XiongJ., GaoY., LiX., LiK., LiQ., ShenJ., HanZ., and ZhangJ. (2020). Losartan Treatment could improve the outcome of TBI mice. Front. Neurol. 11, 992.
70.
ArrojaM.M., ReidE., and McCabeC. (2016). Therapeutic potential of the renin angiotensin system in ischaemic stroke. Exp. Transl. Stroke Med. 8, 8.
71.
VillapolS., and SaavedraJ.M. (2015). Neuroprotective effects of angiotensin receptor blockers. Am. J. Hypertens. 28, 289–299.
72.
HajjarI., OkaforM., McDanielD., ObideenM., DeeE., ShokouhiM., QuyyumiA.A., LeveyA., and GoldsteinF. (2020). Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial. JAMA Netw. Open, 3, e2012252.
73.
McFallA., NicklinS.A., and WorkL.M. (2020). The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: Insight from preclinical stroke studies and therapeutic potential. Cell Signal, 76, 109809.
74.
KhaliliH., AhlR., PaydarS., SjolinG., CaoY., Abdolrahimzadeh FardH., NiakanA., HannaK., JosephB., and MohseniS. (2020). Beta-blocker therapy in severe traumatic brain injury: a prospective randomized controlled trial. World J. Surg. 44, 1844–1853.
75.
BaranovD., and ArmsteadW.M. (2002). Prostaglandins contribute to impaired angiotensin II-induced cerebral vasodilation after brain injury. J. Neurotrauma, 19, 1457–1466.
76.
BaranovD., and ArmsteadW.M. (2003). Selective blockade of AT1 receptor attenuates impairment of hypotensive autoregulation and improves cerebral blood flow after brain injury in the newborn pig. Anesthesiology, 99, 1118–1124.
77.
KehoeP.G. (2018). The coming of age of the angiotensin hypothesis in Alzheimer's disease: progress toward disease prevention and treatment?. J. Alzheimers Dis. 62, 1443–1466.
78.
QiL., JacobA., WangP., and WuR. (2010). Peroxisome proliferator activated receptor-gamma and traumatic brain injury. Int. J. Clin. Exp. Med. 3, 283–292.
79.
WenL., YouW., WangH., MengY., FengJ., and YangX. (2018). Polarization of microglia to the M2 phenotype in a peroxisome proliferator-activated receptor gamma-dependent manner attenuates axonal injury induced by traumatic brain injury in mice. J. Neurotrauma, 35, 2330–2340.
80.
YiJ.H., ParkS.W., BrooksN., LangB.T., and VemugantiR. (2008). PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244, 164–172.
81.
IsmaelS., AhmedH.A., AdrisT., ParveenK., ThakorP., and IshratT. (2021). The NLRP3 inflammasome: a potential therapeutic target for traumatic brain injury. Neural Regen. Res. 16, 49–57.
82.
PatelR.K., PrasadN., KuwarR., HaldarD., and Abdul-MuneerP.M. (2017). Transforming growth factor-beta 1 signaling regulates neuroinflammation and apoptosis in mild traumatic brain injury. Brain Behav. Immun. 64, 244–258.
83.
ZhangD., HuY., SunQ., ZhaoJ., CongZ., LiuH., ZhouM., LiK., and HangC. (2013). Inhibition of transforming growth factor beta-activated kinase 1 confers neuroprotection after traumatic brain injury in rats. Neuroscience, 238, 209–217.
84.
NatunenT.A., GyntherM., RostalskiH., JaakoK., and JalkanenA.J. (2019). Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target. Basic Clin. Pharmacol. Toxicol. 124, 40–49.
85.
CorriganF., ManderK.A., LeonardA.V., and VinkR. (2016). Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation. J. Neuroinflammation, 13, 264.
86.
VinkR., GabrielianL., and ThorntonE. (2017). The role of substance P in secondary pathophysiology after traumatic brain injury. Front. Neurol. 8, 304.
87.
HackeW., KasteM., BluhmkiE., BrozmanM., DavalosA., GuidettiD., LarrueV., LeesK.R., MedeghriZ., MachnigT., SchneiderD., von KummerR., WahlgrenN., ToniD., and InvestigatorsE. (2008). Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317–1329.
88.
MirzahosseiniG., IsmaelS., AhmedH.A., and IshratT. (2021). Manifestation of renin angiotensin system modulation in traumatic brain injury. Metab Brain Dis. 36, 1079–1086.
89.
XiongY., MahmoodA. and ChoppM. (2013). Animal models of traumatic brain injury. Nat. Rev. Neurosci. 14, 128–142.
90.
PageM.J., and SterneJ.A.C. (2021). Assessing risk of bias due to missing results in a synthesis, in: Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 J.P. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M.J. Page, V.A.Welch, (eds). Cochrane. training.cochrane.org/handbook
91.
JacksonD., and TurnerR. (2017). Power analysis for random-effects meta-analysis. Res. Synth. Methods, 8, 290–302.
92.
UngerT. (2003). Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr. Med. Res. Opin. 19, 449–451.
93.
GaitanidisA., BreenK.A., MaurerL.R., SaillantN.N., KaafaraniH.M.A., VelmahosG.C., and MendozaA.E. (2021). Systolic blood pressure <110 mm Hg as a threshold of hypotension in patients with isolated traumatic brain injuries. J. Neurotrauma, 38, 879–885.
94.
PerlmanR.L. (2016). Mouse models of human disease: an evolutionary perspective. Evol. Med. Public Health, 2016, 170–176.
VillapolS., LoaneD.J., and BurnsM.P. (2017). Sexual dimorphism in the inflammatory response to traumatic brain injury. Glia, 65, 1423–1438.
97.
MartinU., ForemanM.A., TravisJ.C., CassonD., and ColemanJ.J. (2008). Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J. Clin. Pharm. Ther. 33, 507–511.
98.
SchwammL.H. (2014). Progesterone for traumatic brain injury—resisting the sirens' song. N. Engl. J. Med. 371, 2522–2523.
99.
Clinicaltrials.gov. (2021). Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF 2021 https://www.clinicaltrials.gov/ct2/show/NCT04533022.
100.
SteckelingsU.M., and SumnersC. (2020). Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin. Sci. (Lond) 134, 2987–3006.
101.
TornlingG., BattaR., PorterJ.C., WilliamsB., BengtssonT., ParmarK., KashivaR., HallbergA., CohrtA.K., WestergaardK., DalsgaardC.J., and RaudJ. (2021). Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial. EClinicalMedicine, 41, 101152.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
